Overview
Dr. Wu is an internal medicine physician and health services researcher. Her main research interest is studying the implementation of precision medicine applications to improve clinical care. She is involved in projects currently looking at a patient-facing family history risk assessment tool, MeTree, which provides individualized risk stratification and clinical decision support recommendations to clinicians and patients. In addition she is also involved in a large scale sequencing program in Singapore looking at the intersection of family health history and genomics to better understand how these data elements can complement one another and create more precise risk predictions. She is a member of NHGRI's IGNITE network as a co-investigator on a multi-site pragmatic clinical trial of the impact of pharmacogenetic testing on management of depression and acute, and chronic pain. She is the implementation science advisor for the VA's Pharmacogenomic Testing for Veterans (PHASER) program, which is working to complete preemptive PGx testing on up to 250,000 Veterans by 2024.
Current Duke Appointments & Affiliations
Adjunct Associate Professor in the Department of Medicine
·
2023 - Present
Medicine, General Internal Medicine,
Medicine
Member of Duke Center for Applied Genomics and Precision Medicine
·
2014 - Present
The Precision Medicine Program,
Medicine
Recent Scholarly Works
Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.
Journal article Pharmacogenomics J · August 5, 2026 We evaluated the effect of CYP2C19 genotype on SSRI response in 114,627 research participants. We graded metabolizer status (0 for ultrarapid metabolizers to 4 for poor metabolizers), and regressed drug response outcomes on these grades. Among participants ... Full text Link to item CiteFactors Facilitating Adoption of Pharmacogenetic Testing by Prescribers of Antidepressants in Four US Health Systems: A Multi-Site Cross-Sectional PGx Implementation Science Study.
Journal article J Pers Med · July 30, 2026 Background: Pharmacogenetic (PGx) testing could identify actionable drug-gene interactions, reducing the risks of inappropriate prescribing of certain medications in some patients. An area of growing public health concern is rising global rates of depressi ... Full text Link to item CiteStreamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform: A Nonrandomized Clinical Trial.
Journal article JAMA Netw Open · April 1, 2026 IMPORTANCE: Approximately 10% of cancers are attributable to heritable germline variants, yet identification of individuals at risk remains suboptimal. OBJECTIVE: To assess the feasibility of personal history and family health history (FHH) risk assessment ... Full text Link to item CiteRecent Grants
Building and Deploying a Genomic-Medicine Risk Assessment Model for Diverse Primary Care Populations.
ResearchInvestigator · Awarded by National Institutes of Health · 2018 - 2025Implementation, Adoption, and Utility of Family History in Diverse Care Settings
ResearchInvestigator · Awarded by National Institutes of Health · 2013 - 2019View All Grants
Education
University of North Carolina, Chapel Hill, School of Medicine ·
2006
M.D.